Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-0159 Safety and PK/PD in Chronic Inducible Urticaria
NCT04548869Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of barzolvolimab in cold urticaria, symptomatic dermographism and Cholinergic Urticaria (CU) (3 arms), sponsored by Celldex Therapeutics. Primary endpoint: Incidence and severity of adverse events at 12 weeks. Started Nov 2020; status: completed.
02
Drugs
barzolvolimab
03
Conditions
cold urticariasymptomatic dermographismCholinergic Urticaria (CU)
Beyond the preview
Go deeper on NCT04548869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548869.